Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form and are able to attend the required visits and follow the study procedures
• People who are 18 years old or older, of any gender
• People who have been diagnosed with advanced endocrine tumours (such as medullary thyroid cancer, thymic carcinoma, or adrenal cortical carcinoma) confirmed by laboratory testing within the past 6 months, where standard treatments have not worked or no standard treatment is available
• People whose genetic testing shows no specific changes in certain immune-related genes (no copy number variations or loss of heterozygosity in HLA-related genes or chromosomal regions) (confirm with trial site)
• People who have advanced or spreading tumours confirmed by tissue testing, with enough frozen tissue or cells available for advanced genetic analysis, and whose results suggest at least one specific tumour marker that may be targeted by their own immune system (confirm with trial site)
• People who are expected to live for at least 4 months
• People who have at least one tumour that can be measured on scans, according to standard imaging criteria
• People whose physical functioning is rated as 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity
• People who have not received certain blood-boosting medications or blood transfusions in the 14 days before their screening tests
• People of childbearing potential (male or female) who agree to use reliable contraception during the trial and for at least 90 days after the last dose; women of childbearing age must have a negative blood pregnancy test within 7 days before the first dose
• People whose virus screening at the start of the trial shows no active infection with CMV, EBV, HIV, hepatitis B, hepatitis C, or syphilis

Who may not be able to join:

• People who have received chemotherapy, hormone therapy, certain traditional medicines with anti-tumour effects, or other anti-tumour treatments within 4 weeks before the first dose (or within 6 weeks for certain specific drugs, or within 5 half-lives for immunotherapy or targeted therapies)
• People who have had major surgery (other than for diagnosis or biopsy) within 4 weeks before the first dose, or who are expected to need major surgery during the study
• People who have previously had a bone marrow or organ transplant, or who plan to have an organ transplant during the study
• People who have previously received another tumour vaccine or cell-based therapy
• People who have brain or spinal cord metastases that are causing symptoms or are considered uncontrolled, as judged by the treating doctor
• People who have had another active or progressing cancer in the past 2 years (with some exceptions for certain fully treated skin or cervical cancers)
• People who have a history of a specific type of lung scarring or inflammation (interstitial lung disease or pulmonary interstitial fibrosis)
• People with a history of serious heart or blood vessel conditions, including certain abnormal heart rhythms, a heart attack, stroke, severe heart failure, or other major cardiovascular events within the past 6 months, or certain heart measurements outside acceptable ranges
• People with other serious uncontrolled health conditions, including severe allergies (including to any component of the study vaccine), immune deficiency disorders, severe liver or kidney disease, poorly controlled blood pressure or diabetes, active stomach or bowel ulcers or bleeding, severe infection requiring hospital treatment or intravenous antibiotics within 4 weeks before the first dose, or active syphilis
• People who have participated in another clinical trial within 4 weeks before the first dose
• People currently taking systemic corticosteroid medications (inhaled corticosteroids are generally acceptable)
• People who are pregnant or breastfeeding
• People whose scans show that the tumour is growing into major blood vessels in a way that suggests a risk of bleeding
• People with significant thyroid function abnormalities, as judged by the treating doctor
• People found to have active pneumonia on their screening chest scan
• People with fluid build-up around the lungs, heart, or in the abdomen that is uncontrolled and requires repeated draining
• People whose side effects from previous cancer treatments have not sufficiently resolved (except for hair loss)
• People with active hepatitis B virus or hepatitis C virus infection confirmed by specific blood tests
• People whom the trial doctor considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.